CliffBio
biologic

Vimizim

elosulfase alfa

Loss of exclusivityFebruary 2026projected — 12-year biologic exclusivity estimate
CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameVimizim
Active ingredientelosulfase alfa
Strength5MG/5ML (1MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2014
Marketing statusRx

More from Biomarin Pharmaceutical

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vimizim patent cliff — loss of exclusivity February 2026 | CliffBio